Previous 10 |
La Jolla Pharmaceutical (NASDAQ: LJPC ) Q4 results highlights: More news on: La Jolla Pharmaceutical Co., Healthcare stocks news, Earnings news and commentary, , Read more ...
La Jolla Pharmaceutical (NASDAQ: LJPC ): Q4 GAAP EPS of -$1.73 beats by $0.07 . More news on: La Jolla Pharmaceutical Co., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today annou...
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced ...
SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on GIAPREZA (angiotensin II) at the Society of Critical Care Medicine’s (SCCM) 48th Critical Care Congress to be held February 17 - 20...
Making a product is just an activity, making a profit on a product is the achievement .” ― Amit Kalantri, Wealth of Words Few stocks have been as controversial in the biotech/biopharma space as La Jolla Pharmaceutical ( LJPC ) . The stock remains down more than 75% since ea...
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ArcBest Corporation (NASDAQ:ARCB), International Game Technology (NYSE...
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
La Jolla Pharmaceutical Company Website:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...